<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Photocure Asa — News on 6ix</title>
<link>https://6ix.com/company/photocure-asa</link>
<description>Latest news and press releases for Photocure Asa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 18 May 2026 15:40:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/photocure-asa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d551adbeedb30cb6f78fb9.webp</url>
<title>Photocure Asa</title>
<link>https://6ix.com/company/photocure-asa</link>
</image>
<item>
<title>AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study</title>
<link>https://6ix.com/company/photocure-asa/news/aua-2026-new-studies-demonstrated-blue-light-cystoscopy-benefits-in-high-risk-nmibc-management-and-cost-comparison-study</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/aua-2026-new-studies-demonstrated-blue-light-cystoscopy-benefits-in-high-risk-nmibc-management-and-cost-comparison-study</guid>
<pubDate>Mon, 18 May 2026 15:40:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association Annual Congress (AUA) 2026. The first highlighted the benefits of Blue Light Cystoscopy (BLC®), notably its diagnostic sensitivity impacting the management of high-risk NMIBC* patients, helping urologists and patients make well-informed decisions. The second abstract investigated the impact of avoiding recurrence in a Blue Light versus White</description>
</item>
<item>
<title>Photocure ASA: Results for the first quarter of 2026</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-first-quarter-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-first-quarter-of-2026</guid>
<pubDate>Thu, 07 May 2026 06:24:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK 125.3 million), and an adjusted EBITDA of NOK 15.3 million (Q1 2025: NOK 9.7 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</description>
</item>
<item>
<title>New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer</title>
<link>https://6ix.com/company/photocure-asa/news/new-health-economic-methodology-published-comparing-cost-effectiveness-of-blc-versus-nbi-imaging-technology-in-bladder-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/new-health-economic-methodology-published-comparing-cost-effectiveness-of-blc-versus-nbi-imaging-technology-in-bladder-cancer-1</guid>
<pubDate>Mon, 04 May 2026 06:32:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication in 'The Journal of Medical Economics' of a novel health economics methodology used to develop the cost-utility model which compared blue light cystoscopy (BLC®) and Narrow Band Imaging (NBI), developed for a health technology appraisal by the Danish Treatment Council last year.The results of that analysis demonstrated that BLC is cost-effective versus NBI, when assessed over the remaining lifetime of the patient.</description>
</item>
<item>
<title>Photocure ASA: Update on Regulatory Classification for OAY Equipment</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-asa-update-on-regulatory-classification-for-oay-equipment-2</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-asa-update-on-regulatory-classification-for-oay-equipment-2</guid>
<pubDate>Mon, 13 Apr 2026 07:30:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed order to reclassify diagnostic endoscopic light source systems (FDA Product Code OAY) under its own initiative per Section 513(f)(3) of the Federal Food, Drug, and Cosmetic Act.</description>
</item>
<item>
<title>Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-trials-in-progress-presented-at-the-european-association-of-urology-eau-2026-congress-aim-to-enable-a-more-personalized-bladder-cancer-care-pathway</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-trials-in-progress-presented-at-the-european-association-of-urology-eau-2026-congress-aim-to-enable-a-more-personalized-bladder-cancer-care-pathway</guid>
<pubDate>Mon, 16 Mar 2026 16:49:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate different stages of the diagnostic pathway, addressing data gaps to improve individual patient care and outcomes.</description>
</item>
<item>
<title>Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions</title>
<link>https://6ix.com/company/photocure-asa/news/asieris-cevira-approved-in-china-as-first-in-class-non-invasive-therapy-for-cervical-precancerous-lesions-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/asieris-cevira-approved-in-china-as-first-in-class-non-invasive-therapy-for-cervical-precancerous-lesions-1</guid>
<pubDate>Tue, 03 Mar 2026 09:55:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China's National Medical Products Administration (NMPA), enabling commercial launch in China.</description>
</item>
<item>
<title>Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-partner-asieris-announces-that-ema-has-accepted-marketing-authorization-application-for-cevira-in-europe-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-partner-asieris-announces-that-ema-has-accepted-marketing-authorization-application-for-cevira-in-europe-1</guid>
<pubDate>Fri, 27 Feb 2026 10:03:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its marketing authorization application (MAA) for Cevira® (APL-1702) for the treatment of high-grade squamous intraepithelial lesions (HSIL) has been accepted by the European Medicines Agency (EMA).</description>
</item>
<item>
<title>Photocure ASA: Results for the fourth quarter of 2025</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-fourth-quarter-of-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-fourth-quarter-of-2025-1</guid>
<pubDate>Wed, 18 Feb 2026 06:44:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and continued operating leverage flow-through in its core Hexvix®/Cysview® commercial business.</description>
</item>
<item>
<title>The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison</title>
<link>https://6ix.com/company/photocure-asa/news/the-impact-of-avoiding-recurrence-new-bravo-study-abstract-at-suo-2025-demonstrates-cost-neutrality-in-blue-light-versus-white-light-cystoscopy-comparison-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/the-impact-of-avoiding-recurrence-new-bravo-study-abstract-at-suo-2025-demonstrates-cost-neutrality-in-blue-light-versus-white-light-cystoscopy-comparison-1</guid>
<pubDate>Mon, 08 Dec 2025 07:30:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting (SUO) December 2-5, 2025, in Phoenix, AZ. The abstract 'COSTS OF CARE AND ONCOLOGIC OUTCOMES ASSOCIATED WITH BLUE LIGHT CYSTOSCOPY IN AN EQUAL ACCESS SETTING: RESULTS FROM THE BRAVO STUDY' compares costs in non-muscle-invasive bladder cancer (NMIBC) care, incurred by white light cystoscopy (WLC) versus blue li</description>
</item>
<item>
<title>New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management</title>
<link>https://6ix.com/company/photocure-asa/news/new-budget-impact-model-study-in-4-european-countries-concludes-that-blc-use-offers-a-clinically-meaningful-and-economically-rational-approach-to-nmibc-management-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/new-budget-impact-model-study-in-4-european-countries-concludes-that-blc-use-offers-a-clinically-meaningful-and-economically-rational-approach-to-nmibc-management-1</guid>
<pubDate>Wed, 19 Nov 2025 07:34:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The influence of differing European health care payment systems on the potential financial impact of adoption" in the Journal of Medical Economics this week. The research objective was to compare the economic implications of blue light cystoscopy (BLC®) adoption in line with national guide</description>
</item>
<item>
<title>Photocure ASA: Results for the third quarter of 2025</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-third-quarter-of-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-third-quarter-of-2025-1</guid>
<pubDate>Wed, 29 Oct 2025 06:27:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 million) for the company. Looking ahead, Photocure expects product revenue growth in the range of 8% to 10% on a constant currency basis (compared to 7 to 11% previously) and an EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued</description>
</item>
<item>
<title>Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-and-intelligent-scopes-corporation-partner-on-development-of-ai-for-blue-light-cystoscopy-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-and-intelligent-scopes-corporation-partner-on-development-of-ai-for-blue-light-cystoscopy-1</guid>
<pubDate>Wed, 15 Oct 2025 15:25:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with blue light cystoscopy (BLC®). Initial testing shows promising performance results.</description>
</item>
<item>
<title>Nokia expands defense portfolio with two advanced tactical communication solutions</title>
<link>https://6ix.com/company/photocure-asa/news/nokia-expands-defense-portfolio-with-two-advanced-tactical-communication-solutions-472</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/nokia-expands-defense-portfolio-with-two-advanced-tactical-communication-solutions-472</guid>
<pubDate>Tue, 09 Sep 2025 07:00:00 GMT</pubDate>
<description>Nokia Mission-Safe Phone Nokia Mission-Safe Phone Nokia Banshee 5G Tactical Radio Nokia Banshee 5G Tactical Radio Press Release Nokia expands defense portfolio with two advanced tactical communication solutions Introduces Nokia Mission-Safe Phone, a purpose-built defense smartphone for reliable mission-critical communications in the harshest operational environmentsNokia also launches the upgraded Banshee 5G Tactical Radio, a rugged, portable, easy-to-deploy network hub, now with integrated 5G c</description>
</item>
<item>
<title>Photocure ASA: Results for the second quarter of 2025</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-second-quarter-of-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-second-quarter-of-2025-1</guid>
<pubDate>Wed, 30 Jul 2025 05:10:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and an EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating le</description>
</item>
<item>
<title>Photocure ASA: Results for the first quarter of 2025</title>
<link>https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-first-quarter-of-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/photocure-asa-results-for-the-first-quarter-of-2025-1</guid>
<pubDate>Thu, 08 May 2025 05:08:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million), and an EBITDA of NOK 1.8 million (7.9) for the company. Photocure expects product revenue growth in the range of 7% to 11% and YoY EBITDA improvement in 2025. While the Company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in mileston</description>
</item>
<item>
<title>Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making</title>
<link>https://6ix.com/company/photocure-asa/news/bladder-cancer-presentations-at-aua2025-blue-light-cystoscopy-improves-risk-stratification-and-informed-decision-making-1</link>
<guid isPermaLink="true">https://6ix.com/company/photocure-asa/news/bladder-cancer-presentations-at-aua2025-blue-light-cystoscopy-improves-risk-stratification-and-informed-decision-making-1</guid>
<pubDate>Tue, 29 Apr 2025 06:24:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.</description>
</item>
</channel>
</rss>